G
GluBio Therapeutics
Engages in molecular glue-targeted protein degradation drug discovery
About GluBio Therapeutics
GluBio Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines through targeted protein degradation (TPD). The company operates in the biotechnology sector, primarily serving patients with unmet medical needs across various therapeutic areas. GluBio's proprietary TPD discovery platform and advanced screening capabilities enable the creation of highly selective small molecule degraders. Headquartered in San Diego, CA, with research operations in the United States and China, GluBio leverages its seasoned team of drug developers to advance its diverse pipeline. The business model revolves around the research and development of novel therapies, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of these therapies, partnerships, and potential licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 73.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Medical Research, Drug Development, Research and Development, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Feb 2026 | $30M | $120M | Sanofi | ↗ |
| SERIES AOther financing | Aug 2022 | $22M | $88M | Lilly Asia Ventures · Kaitai Capital · Qiming Venture Partners | ↗ |
Growth signals
Latest recorded traffic for GluBio Therapeutics is 1.1K monthly website visits, up 189.5% over the last three months. GluBio Therapeutics's team grew 9.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
GluBio Therapeutics in its local ecosystem
The GluBio Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Legend Capital
Lilly Asia Ventures- KCKaitai Capital
- K2K2VC
Qiming Venture Partners
E Fund Management
Sanofi
Source: Dealroom Talent Intelligence.
See GluBio Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









